Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Executes Stock Sales Under 10b5-1 Plan

Christopher Gibson, CEO of Recursion Pharmaceuticals, executed sales of Class A Common Stock on September 4th and 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Christopher Gibson, the CEO of Recursion Pharmaceuticals, sold 20,000 shares of Class A Common Stock on both September 4th and September 5th, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 27, 2023.
• The sales occurred at prices of $6.04 and $6.14 per share on September 4th and 5th, respectively.
• These transactions also involved the automatic conversion of Class B Common Stock into Class A Common Stock.
• Following these transactions, Gibson directly owns 762,656 shares of Class A Common Stock.
• Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports stock sales under a pre-arranged plan, which is a common practice. There's no indication of positive or negative news about the company itself.

Industry Context

Insider trading activity is always closely watched by investors. Sales by a CEO can sometimes be interpreted negatively, but the presence of a pre-arranged 10b5-1 plan mitigates this concern as it indicates the transactions were planned well in advance.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, especially in the biotech sector, to utilize 10b5-1 trading plans to diversify their holdings and manage personal finances.
• Comparable companies like Exscientia or Schrodinger also see regular Form 4 filings from their executives.
• The size of the transactions (20,000 shares each day) is relatively small compared to the total outstanding shares and the CEO's overall holdings, suggesting it's likely routine portfolio management rather than a major shift in sentiment.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they interpret the sales negatively, despite the existence of the 10b5-1 plan.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely negligible.

Key Dates